PAI
URGN icon

ProQuest Associates IV’s UroGen Pharma URGN Stock Holding History

ProQuest Associates IV’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$37.3M Hold
789,297
– – 70.39% 1
2018
Q2 		$39.3M Sell
789,297
-306,727
-28% -$17.9M 60.44% 1
2018
Q1 		$54.5M Hold
1,096,024
– – 62.61% 1
2017
Q4 		$40.8M Sell
1,096,024
-353,721
-24% -$12.6M 54.17% 1
2017
Q3 		$45.7M Sell
1,449,745
-1,584
-0.1% -$35K 45.77% 1
2017
Q2 		$26.2M Buy
+1,451,329
New +$25.2M 33.51% 1

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
HCM
Highline Capital Management New York $51.6M AUM 21.72% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.5B AUM 68.34% 1-Year Est. Return